BioNTech Research Development from 2010 to 2026

BNTX Stock  USD 108.88  4.87  4.28%   
BioNTech Research Development yearly trend continues to be fairly stable with very little volatility. Research Development is likely to outpace its year average in 2026. During the period from 2010 to 2026, BioNTech Research Development regression line of annual values had r-squared of  0.77 and arithmetic mean of  796,253,559. View All Fundamentals
 
Research Development  
First Reported
2018-03-31
Previous Quarter
509.1 M
Current Value
564.8 M
Quarterly Volatility
205.5 M
 
Covid
 
Interest Hikes
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Net Interest Income of 513.2 M, Interest Income of 528.4 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 10.38, Dividend Yield of 0.011 or PTB Ratio of 1.27. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
Build AI portfolio with BioNTech Stock
Check out the analysis of BioNTech Correlation against competitors.
The evolution of Research Development for BioNTech SE provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BioNTech compares to historical norms and industry peers.

Latest BioNTech's Research Development Growth Pattern

Below is the plot of the Research Development of BioNTech SE over the last few years. It is BioNTech's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

BioNTech Research Development Regression Statistics

Arithmetic Mean796,253,559
Geometric Mean311,656,716
Coefficient Of Variation123.30
Mean Deviation830,618,253
Median143,066,000
Standard Deviation981,749,609
Sample Variance963832.3T
Range2.6B
R-Value0.88
Mean Square Error232075.2T
R-Squared0.77
Slope171,070,652
Total Sum of Squares15421316.7T

BioNTech Research Development History

20262.7 B
20252.6 B
20242.3 B
20231.8 B
20221.5 B
2021949.2 M
2020645 M

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development2.6 B2.7 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.